Vitamin D treatment for patients with bronchiectasis
Prospective Clinical Study on Vitamin D Replacement in Bronchiectasis - A Pilot Study
This study is testing if vitamin D supplements can help people with bronchiectasis who have low vitamin D levels experience fewer flare-ups.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 104 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Queen Mary Hospital, Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06551337 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of vitamin D replacement on reducing the occurrence of bronchiectasis exacerbations in patients with vitamin D deficiency. It is a self-controlled pilot study that invites participants from a previous related study to assess the impact of vitamin D3 supplementation. Participants will have their blood levels of 25-hydroxyvitamin D monitored throughout the study. The aim is to provide insights into the potential benefits of vitamin D in managing bronchiectasis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of non-CF bronchiectasis and who participated in a prior related study.
Not a fit: Patients with underlying asthma, COPD, other respiratory diseases, osteoporosis, or those already taking vitamin D supplements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for bronchiectasis patients, potentially reducing hospitalizations due to exacerbations.
How similar studies have performed: Previous studies have explored vitamin D's role in respiratory conditions, but this specific approach in bronchiectasis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ages 18 years or above, male or female. 2. confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed tomography (HRCT) scan. 3. participation in the prior study entitled "Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation" (UW 22-317) Exclusion Criteria: 1. underlying asthma, COPD and other co-existing respiratory diseases 2. underlying osteoporosis 3. supplementary Vitamin D in their regimen 4. advanced chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 30mL/min
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Wang Chun Kwok, MBBS
- Email: kwokwch@hku.hk
- Phone: 2255 3111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.